DREADD
Designer receptors exclusively activated by designer drugs (DREADDs) are genetically engineered GPCRs that are activated by physiologically inert synthetic small molecules (designer drugs) but not their endogenous ligand. Read our DREADDs mini-review or for practical advice on using these ligands in the lab see Stability of Water-Soluble DREADD Ligands in Solution: A Technical Review and Clozapine N-Oxide (freebase) - a technical review on stability, solubility and use in the lab).
Recombinant human BDNF protein (HB3485)
Description:Member of the neurotrophin growth factor family. Plays an important role in synaptic plasticity and neurogenesis.
Clozapine N-oxide (CNO) (freebase) (HB1807)
Description:Prototypical DREADD activator. Clozapine metabolite.
Purity:>98%
- Description:
Dihydrochloride salt of CNO - the prototypical DREADD activator
Purity:>98%
EC 23 (HB2592)
Description:Synthetic retinoid. Induces neural differentiation of hESCs.
Purity:>99%
Homovanillic acid (HB1902)
Description:Fluorimetric reagent. Catecholamine metabolite.
Purity:>99%
(Z)-4-Hydroxytamoxifen (Z-4-OHT) (HB2508)
Description:Synthetic estrogen receptor ligand. Widely used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>98%
- Description:
Synthetic estrogen receptor ligand. Widely used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>98%
- Description:
Estrogen receptor ligand. For inducible genome manipulation (e.g. Cre-LoxP (CreER)/ TRAP/ CRISPR-Cas9).
Purity:>98%